# Jyong Biotech Ltd. (MENS)

Source: https://www.quantisnow.com/company/MENS
Generated: 2026-11-15T08:10:09.699Z

- Ticker: MENS
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- IPO year: 2025
- SEC CIK: 0001954488

## Latest MENS news and filings

- 2026-10-21 12:00 UTC [Jyong Biotech to Host Two-Day Investor Events in Silicon Valley and Irvine, California](https://www.quantisnow.com/insight/jyong-biotech-to-host-two-day-investor-events-in-silicon-valley-6752945)
- 2026-10-15 12:00 UTC [Jyong Biotech Announces Proposed Texas Facility to Support Potential Commercialization of Its Drug Candidates](https://www.quantisnow.com/insight/jyong-biotech-announces-proposed-texas-facility-to-support-potential-commercialization-6747315)
- 2026-09-03 12:00 UTC [Leadership Update] [Jyong Biotech Announces Participation in StockFan Virtual Investor Non-Deal Roadshow](https://www.quantisnow.com/insight/jyong-biotech-announces-participation-in-stockfan-virtual-investor-non-deal-roadshow-6704278)
- 2026-07-23 14:52 UTC [Jyong Biotech Highlights Multi-Billion Dollar Global BPH Market Opportunity and Reaffirms Strategic Focus on Global Licensing Partnerships](https://www.quantisnow.com/insight/jyong-biotech-highlights-multi-billion-dollar-global-bph-market-opportunity-and-6646644)
- 2026-07-02 12:00 UTC [Jyong Biotech Showcases Botanical Drug Portfolio at BIO 2026 International Convention](https://www.quantisnow.com/insight/jyong-biotech-showcases-botanical-drug-portfolio-at-bio-2026-international-6624237)
- 2026-05-29 12:00 UTC [Jyong Biotech CEO Outlines FDA Pathway and Global Strategy in PharmaBoardroom Live Interview](https://www.quantisnow.com/insight/jyong-biotech-ceo-outlines-fda-pathway-and-global-strategy-in-6578367)
- 2026-05-15 12:30 UTC [Jyong Biotech Ltd. Files Annual Report on Form 20-F for Fiscal Year 2025](https://www.quantisnow.com/insight/jyong-biotech-ltd-files-annual-report-on-form-20-f-for-6555940)
- 2026-05-15 01:52 UTC [SEC Form 20-F filed by Jyong Biotech Ltd.](https://www.quantisnow.com/insight/sec-form-20-f-filed-by-jyong-biotech-ltd-6555377)
- 2026-04-29 17:11 UTC [SEC Form NT 20-F filed by Jyong Biotech Ltd.](https://www.quantisnow.com/insight/sec-form-nt-20-f-filed-by-jyong-biotech-ltd-6520732)
- 2026-04-14 15:46 UTC [SEC Form 3] [SEC Form 3 filed by new insider Zhang Wei (Vivi)](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-zhang-wei-vivi-6499202)
- 2026-04-08 14:11 UTC [SEC Form 3] [SEC Form 3 filed by new insider Kuo Fu-Feng](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-kuo-fu-feng-6492533)
- 2026-04-01 19:43 UTC [SEC Form 3] [SEC Form 3 filed by new insider Hsu Ming Tsan](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-hsu-ming-tsan-6481674)
- 2026-04-01 19:34 UTC [SEC Form 3] [SEC Form 3 filed by new insider Hsu Feng-Lin](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-hsu-feng-lin-6481658)
- 2026-04-01 19:20 UTC [SEC Form 3] [SEC Form 3 filed by new insider Hsu Feng-Lin](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-hsu-feng-lin-6481625)
- 2026-04-01 19:10 UTC [SEC Form 3] [SEC Form 3 filed by new insider Fan Hung-Shu](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-fan-hung-shu-6481605)
- 2026-04-01 18:56 UTC [SEC Form 3] [SEC Form 3 filed by new insider Chi Pang-Chieh](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-chi-pang-chieh-6481590)
- 2026-03-27 12:30 UTC [Jyong Biotech Updates the Potential Clinical Benefits and Advantages of Its Plant-Derived Innovative Drug MCS®-2](https://www.quantisnow.com/insight/jyong-biotech-updates-the-potential-clinical-benefits-and-advantages-of-6472890)
- 2026-02-12 13:30 UTC [Jyong Biotech Reports Transformative Period of Clinical Validation and Commercialization Attempt: Phase II Data Focuses on Dual Therapeutic Potential of MCS-8 in Oncology and Metabolic Health, Alongside Strategic Market Entry into Asia](https://www.quantisnow.com/insight/jyong-biotech-reports-transformative-period-of-clinical-validation-and-commercialization-6388475)
- 2026-02-06 21:31 UTC [SEC Form 6-K] [SEC Form 6-K filed by Jyong Biotech Ltd.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-jyong-biotech-ltd-6380010)
- 2026-01-30 13:30 UTC [Jyong Biotech Subsidiary Announces Phase II Clinical Data on Cholesterol and LDH Indicators for MCS-8 (PCP), Indicating Potential in Prostate Cancer Prevention and Metabolic Value](https://www.quantisnow.com/insight/jyong-biotech-subsidiary-announces-phase-ii-clinical-data-on-cholesterol-6367171)
- 2026-01-09 21:30 UTC [SEC Form 6-K] [SEC Form 6-K filed by Jyong Biotech Ltd.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-jyong-biotech-ltd-6344521)
- 2025-12-19 14:00 UTC [Jyong Biotech Responds to Share Price and Volume Movement](https://www.quantisnow.com/insight/jyong-biotech-responds-to-share-price-and-volume-movement-6323250)
- 2025-12-04 13:30 UTC [Jyong Biotech Expands Regional Partnerships, Signs MOU with a Vietnam Pharmaceutical Distributor for MCS‑2 Market Entry](https://www.quantisnow.com/insight/jyong-biotech-expands-regional-partnerships-signs-mou-with-a-vietnam-6303018)
- 2025-11-24 13:30 UTC [Jyong Biotech Ltd. Signs Non‑Binding Letter of Intent with Leading South Korean Pharmaceutical Company to Evaluate In‑Licensing of Plant-Derived MCS Drugs](https://www.quantisnow.com/insight/jyong-biotech-ltd-signs-nonbinding-letter-of-intent-with-leading-6291197)
- 2025-11-20 13:30 UTC [Jyong Biotech Announces Completion of Primary Endpoint Statistical Analysis for Phase II Clinical Trial of MCS-8 With Positive Outcomes](https://www.quantisnow.com/insight/jyong-biotech-announces-completion-of-primary-endpoint-statistical-analysis-for-6288203)
- 2025-09-29 12:30 UTC [Jyong Biotech Wins Innovation Gold Award in Pharmaceutical Category at 2025 Taipei Biotech Awards](https://www.quantisnow.com/insight/jyong-biotech-wins-innovation-gold-award-in-pharmaceutical-category-at-6213941)
- 2025-09-18 12:30 UTC [Jyong Biotech Chairwoman and CEO Set to Attend as Speaker at 2025 Global Business Forum in Taipei](https://www.quantisnow.com/insight/jyong-biotech-chairwoman-and-ceo-set-to-attend-as-speaker-6205080)
- 2025-09-16 12:18 UTC [Jyong Biotech Announces Completion of Patient Enrollment of over 700 subjects in Phase II Clinical Trial of MCS‑8 for Prostate Cancer Prevention](https://www.quantisnow.com/insight/jyong-biotech-announces-completion-of-patient-enrollment-of-over-700-6201899)
- 2025-08-22 13:00 UTC [Jyong Biotech Ltd. Participated in the 22nd Urological Association of Asia Congress to Display the Clinical Data for its Phase III Studies of BOTRESO and Phase II Study of MCS-8 (PCP)](https://www.quantisnow.com/insight/jyong-biotech-ltd-participated-in-the-22nd-urological-association-of-6175704)
- 2025-07-22 14:40 UTC [Jyong Biotech Ltd. Rings Nasdaq Bell and Participates at the BIO 2025 International Convention](https://www.quantisnow.com/insight/jyong-biotech-ltd-rings-nasdaq-bell-and-participates-at-the-6127982)
- 2025-06-30 20:05 UTC [SEC Form SP 15D2 filed by Jyong Biotech Ltd.](https://www.quantisnow.com/insight/sec-form-sp-15d2-filed-by-jyong-biotech-ltd-6103641)
- 2025-06-18 21:20 UTC [Public Offering] [Jyong Biotech Ltd. Announces Closing of $20 Million Initial Public Offering](https://www.quantisnow.com/insight/jyong-biotech-ltd-announces-closing-of-20-million-initial-public-6092334)
- 2025-06-18 12:00 UTC [SEC Form 424B4 filed by Jyong Biotech Ltd.](https://www.quantisnow.com/insight/sec-form-424b4-filed-by-jyong-biotech-ltd-6091166)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/MENS
- Earnings history: https://www.quantisnow.com/earnings/MENS
- Dividend history: https://www.quantisnow.com/dividends/MENS
- Insider transactions: https://www.quantisnow.com/insiders/MENS
- Options chain: https://www.quantisnow.com/options/MENS
- SEC 8-K filings only: https://www.quantisnow.com/company/MENS/8-k
- RSS and alerts for MENS: https://www.quantisnow.com/docs/rss-feeds.md